Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,526 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of Fluoro-[18F]-Deoxy-2-D-Glucose Positron Emission Tomography/Computed Tomography to Predict Immunotherapy Treatment Response in Patients With Squamous Cell Oral Cavity Cancers.
Shah H, Wang Y, Cheng SC, Gunasti L, Chen YH, Lako A, Guenette J, Rodig S, Jo VY, Uppaluri R, Haddad R, Schoenfeld JD, Jacene HA. Shah H, et al. JAMA Otolaryngol Head Neck Surg. 2022 Mar 1;148(3):268-276. doi: 10.1001/jamaoto.2021.4052. JAMA Otolaryngol Head Neck Surg. 2022. PMID: 35050348 Free PMC article. Clinical Trial.
Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
Jacene HA, Youn T, DiPiro PJ, Hu J, Cheng SC, Franchetti Y, Shah H, Bellon JR, Warren L, Schlosnagle E, Nakhlis F, Rosenbluth J, Yeh E, Overmoyer B; Dana-Farber Cancer Institute Inflammatory Breast Cancer Program. Jacene HA, et al. Among authors: shah h. Clin Breast Cancer. 2019 Apr;19(2):146-155. doi: 10.1016/j.clbc.2018.11.010. Epub 2018 Nov 26. Clin Breast Cancer. 2019. PMID: 30584057
Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial.
Schoenfeld JD, Hanna GJ, Jo VY, Rawal B, Chen YH, Catalano PS, Lako A, Ciantra Z, Weirather JL, Criscitiello S, Luoma A, Chau N, Lorch J, Kass JI, Annino D, Goguen L, Desai A, Ross B, Shah HJ, Jacene HA, Margalit DN, Tishler RB, Wucherpfennig KW, Rodig SJ, Uppaluri R, Haddad RI. Schoenfeld JD, et al. JAMA Oncol. 2020 Oct 1;6(10):1563-1570. doi: 10.1001/jamaoncol.2020.2955. JAMA Oncol. 2020. PMID: 32852531 Free PMC article. Clinical Trial.
Clinical Implementation of 177Lu-PSMA-617 in the United States: Lessons Learned and Ongoing Challenges.
Ravi P, Whelpley B, Kelly E, Wolanski A, Ritzer J, Robertson M, Shah H, Morgans AK, Wei XX, Sunkara R, Pomerantz M, Taplin ME, Kilbridge KL, Choudhury AD, Jacene H. Ravi P, et al. Among authors: shah h. J Nucl Med. 2023 Mar;64(3):349-350. doi: 10.2967/jnumed.122.265194. Epub 2023 Jan 26. J Nucl Med. 2023. PMID: 36702553 Free article. No abstract available.
Hepatobiliary Scintigraphy: A Case-based Review.
Mario J, Dietsche E, Halpern J, Schneider A, Sakellis C, Jacene H, Shah H. Mario J, et al. Among authors: shah h. Radiographics. 2023 Sep;43(9):e220104. doi: 10.1148/rg.220104. Radiographics. 2023. PMID: 37590160 No abstract available.
2,526 results